Cover Image
市場調查報告書

轉移性黑色素瘤:開發平台分析

Metastatic Melanoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229728
出版日期 內容資訊 英文 648 Pages
訂單完成後即時交付
價格
Back to Top
轉移性黑色素瘤:開發平台分析 Metastatic Melanoma - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 648 Pages
簡介

所謂轉移性黑色素瘤(別名:第四期黑色素瘤)是指各種黑色素瘤細胞(皮膚、黏膜、眼窩等)透過淋巴結轉移到人體的各個組織之狀態。尤其是轉移到肝、肺、骨、腦的可能性相當高。主要症狀有淋巴結腫脹(尤其是腋下、鼠蹊部)、原因不明的體重減輕、頭痛、癲癇發作等。主要治療法有外科手術及放射線治療、化療、以及這些療法的複合療法。

本報告提供全球各國治療轉移性黑色素瘤所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

轉移性黑色素瘤概要

治療藥的開發

  • 轉移性黑色素瘤開發中產品:概要
  • 轉移性黑色素瘤開發中產品:比較分析

各企業開發中的轉移性黑色素瘤治療藥

大學/研究機關研究中的轉移性黑色素瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

轉移性黑色素瘤治療藥:開發中的產品的一覽(各企業)

轉移性黑色素瘤治療藥:研究中的產品的一覽(大學/研究機關別)

轉移性黑色素瘤開發治療藥的企業

轉移性黑色素瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

轉移性黑色素瘤治療藥:開發中產品的最新趨勢

轉移性黑色素瘤治療藥:開發暫停的產品

轉移性黑色素瘤治療藥:開發中止的產品

轉移性黑色素瘤相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8473IDB

Summary

Global Markets Direct's, 'Metastatic Melanoma - Pipeline Review, H2 2016', provides an overview of the Metastatic Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Melanoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
  • The report reviews pipeline therapeutics for Metastatic Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Melanoma therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Melanoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Metastatic Melanoma Overview
  • Therapeutics Development
  • Metastatic Melanoma - Therapeutics under Development by Companies
  • Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Melanoma - Pipeline Products Glance
  • Metastatic Melanoma - Products under Development by Companies
  • Metastatic Melanoma - Products under Investigation by Universities/Institutes
  • Metastatic Melanoma - Companies Involved in Therapeutics Development
  • Metastatic Melanoma - Therapeutics Assessment
  • Drug Profiles
  • Metastatic Melanoma - Dormant Projects
  • Metastatic Melanoma - Discontinued Products
  • Metastatic Melanoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Metastatic Melanoma, H2 2016
  • Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Melanoma - Pipeline by AB Science SA, H2 2016
  • Metastatic Melanoma - Pipeline by AbbVie Inc, H2 2016
  • Metastatic Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Metastatic Melanoma - Pipeline by Affichem SA, H2 2016
  • Metastatic Melanoma - Pipeline by Agalimmune Ltd, H2 2016
  • Metastatic Melanoma - Pipeline by AGV Discovery, SAS, H2 2016
  • Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H2 2016
  • Metastatic Melanoma - Pipeline by Amgen Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Angimmune LLC, H2 2016
  • Metastatic Melanoma - Pipeline by Apexigen, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Array BioPharma Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by AstraZeneca Plc, H2 2016
  • Metastatic Melanoma - Pipeline by Basilea Pharmaceutica Ltd., H2 2016
  • Metastatic Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by BerGenBio AS, H2 2016
  • Metastatic Melanoma - Pipeline by Bioncotech Therapeutics SL, H2 2016
  • Metastatic Melanoma - Pipeline by Bionomics Limited, H2 2016
  • Metastatic Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Metastatic Melanoma - Pipeline by Calithera Biosciences, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Cellceutix Corporation, H2 2016
  • Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Cortice Biosciences, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H2 2016
  • Metastatic Melanoma - Pipeline by Dynavax Technologies Corporation, H2 2016
  • Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H2 2016
  • Metastatic Melanoma - Pipeline by Eli Lilly and Company, H2 2016
  • Metastatic Melanoma - Pipeline by Ensol Biosciences Inc., H2 2016
  • Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Metastatic Melanoma - Pipeline by Galapagos NV, H2 2016
  • Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Metastatic Melanoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Ignyta, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Immune Design Corp., H2 2016
  • Metastatic Melanoma - Pipeline by Immunocore Limited, H2 2016
  • Metastatic Melanoma - Pipeline by ImmuRx, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Incyte Corporation, H2 2016
  • Metastatic Melanoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by IO Biotech ApS, H2 2016
  • Metastatic Melanoma - Pipeline by Lentigen Technology, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H2 2016
  • Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H2 2016
  • Metastatic Melanoma - Pipeline by MacroGenics, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by MedImmune, LLC, H2 2016
  • Metastatic Melanoma - Pipeline by Medivation, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by MELEMA Pharma GmbH , H2 2016
  • Metastatic Melanoma - Pipeline by Merck & Co., Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Merck KGaA, H2 2016
  • Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Metastatic Melanoma - Pipeline by Modulate Therapeutics, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Moleculin Biotech Inc, H2 2016
  • Metastatic Melanoma - Pipeline by Morphotek, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by NewLink Genetics Corporation, H2 2016
  • Metastatic Melanoma - Pipeline by Novartis AG, H2 2016
  • Metastatic Melanoma - Pipeline by Omeros Corporation, H2 2016
  • Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Metastatic Melanoma - Pipeline by OncoSec Medical Incorporated, H2 2016
  • Metastatic Melanoma - Pipeline by Onxeo SA, H2 2016
  • Metastatic Melanoma - Pipeline by Pfizer Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Pharmis Biofarmaceutica, Lda., H2 2016
  • Metastatic Melanoma - Pipeline by Philogen S.p.A., H2 2016
  • Metastatic Melanoma - Pipeline by PinCell srl, H2 2016
  • Metastatic Melanoma - Pipeline by Plexxikon Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Prima BioMed Ltd., H2 2016
  • Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Provenance Biopharmaceuticals Corp., H2 2016
  • Metastatic Melanoma - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Recepta Biopharma S.A., H2 2016
  • Metastatic Melanoma - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
  • Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H2 2016
  • Metastatic Melanoma - Pipeline by Sillajen Biotherapeutics, H2 2016
  • Metastatic Melanoma - Pipeline by SolaranRx, Inc., H2 2016
  • Metastatic Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016
  • Metastatic Melanoma - Pipeline by Takara Bio Inc., H2 2016
  • Metastatic Melanoma - Pipeline by TC BioPharm Limited, H2 2016
  • Metastatic Melanoma - Pipeline by Tikcro Technologies, Ltd., H2 2016
  • Metastatic Melanoma - Pipeline by Ultimovacs AS, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Melanoma - Dormant Projects, H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..1), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..2), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..3), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..4), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..5), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..6), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..7), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..8), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..9), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..10), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..11), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..12), H2 2016
  • Metastatic Melanoma - Dormant Projects (Contd..13), H2 2016
  • Metastatic Melanoma - Discontinued Products, H2 2016
  • Metastatic Melanoma - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Metastatic Melanoma, H2 2016
  • Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top